Eli Lilly price target raised to $1,025 from $913 at Barclays

Barclays raised the firm’s price target on Eli Lilly to $1,025 from $913 and keeps an Overweight rating on the shares as part of a Q2 earnings preview for the U.S. biopharmaceutical space. The analyst believes Pfizer (PFE), Eli Lilly (LLY) and Merck (MRK) “are set up for compelling updates,” while Travere Therapeutics’ (TVTX) momentum should continue into the FDA action date.